Hematopoietic gene therapy has markedly progressed during the last 15 years both in terms of safety and efficacy. While a number of serious adverse events (SAE) were initially generated as a consequence of genotoxic insertions of gamma-retroviral vectors in the cell genome, no SAEs and excellent outcomes have been reported in patients infused with autologous hematopoietic stem cells (HSCs) transduced with self-inactivated lentiviral and gammaretroviral vectors. Advances in the field of HSC gene therapy have extended the number of monogenic diseases that can be treated with these approaches. Nowadays, evidence of clinical efficacy has been shown not only in primary immunodeficiencies, but also in other hematopoietic diseases, including beta-thalassemia and sickle cell anemia. In addition to the rapid progression of non-targeted gene therapies in the clinic, new approaches based on gene editing have been developed thanks to the discovery of designed nucleases and improved non-integrative vectors, which have markedly increased the efficacy and specificity of gene targeting to levels compatible with its clinical application. Based on advances achieved in the field of gene therapy, it can be envisaged that these therapies will soon be part of the therapeutic approaches used to treat life-threatening diseases of the hematopoietic system.
| INTRODUCTION
While transplantation of allogeneic hematopoietic stem cells (HSCs) from healthy donors constitutes the standard therapy for patients with inherited hematopoietic diseases, the proportion of patients with HLA compatible donors is limited. Additionally, significant side effects mainly related to graft vs host disease (GVHD), infections and graft failure are associated to this therapeutic intervention. Due to these limitations, and because of advances in the development of gene therapy, the genetic correction of autologous HSCs is becoming an alternative therapeutic option to allogeneic transplantation in inherited hematopoietic diseases.
Based on the self-renewing and multi-potent properties of primitive HSCs, these rare bone marrow (BM) cells were considered an ideal target to correct genetic defects characteristic of inherited hematopoietic diseases. HSCs are responsible for the long-term generation of peripheral blood (PB) T-and B-lymphocytes, natural killer cells, monocytes, granulocytes, eosinophils, basophils, macrophages, erythrocytes and platelets. 1 Therefore, any monogenic disease associated with defects in blood cells could be potentially treated by means of the genetic correction of the HSCs. Despite the clinical efficacy of the first gene therapy trials conducted in patients with X-linked severe common immunodeficiency (SCID-X1) [2] [3] [4] and ADA-SCID, 5, 6 and later on in chronic granulomatous disease (CGD) 7 and Wiscott-Aldrich (WAS) patients, 8 risks associated to the use of gamma-retroviral vectors (RVs) were observed in several patients whose HSCs were transduced with these vectors. [7] [8] [9] [10] [11] [12] [13] Nevertheless, the generation of self-inactivated lentiviral (SIN-LV) and gamma-retroviral vectors (SIN-RVs) has had an enormous impact on the clinical development of gene therapy since in addition to their clinical efficacy, no serious adverse events (SAEs) have been reported in patients treated with these new vectors.
Advances in the gene therapy of primary immunodeficiencies, β-hemoglobinopathies and bone marrow failure (BMF) syndromes will be described in this review. Additionally, the evolvement of HSC gene editing will be discussed due to its rapid progression.
| GENE THERAPY IN PRIMARY IMMUNODEFICIENCIES
Primary immunodeficiencies (PIDs) are a heterogeneous group of rare diseases associated with defects either in the number or the function of cells of the immune system. PIDs comprise a group of more than 300 genetic defects affecting the most important system responsible for protection against infections and cancer. 14, 15 Depending on the specific PID, their incidence varies enormously. 16 Additionally, since the proper functioning of the immune system is required from the first weeks of life, PIDs frequently become life-threatening diseases that appear early in childhood. Clinical symptoms are heterogeneous, and are generally associated with a high rate of infections and even mortality. The only curative treatment for PIDs, besides ADA-SCID for which enzyme replacement has proven to be partially effective, 17 is hematopoietic stem cell transplantion (HSCT). 18 Outcomes of HSCT for PIDs have markedly improved after the first transplants were performed in WAS 19 and SCID 20 patients. Nevertheless, the possibility of finding a matched donor for patients with a severe PID is limited, in many instances due to the necessity of performing the transplant during the first months of life. Gene therapy was thus considered a good alternative for many of these patients, which led to a longer life expectancy of PID patients. 15 Clinical trials in patients with SCID-X1 2-4,21 and ADA-SCID 5, 6 clearly showed the benefit of gene therapy in PIDs. In both cases, RVs were used to facilitate the insertion of the therapeutic gene in patient HSCs. Unfortunately, 2 years after the initiation of the SCID-X1 trials SAEs consisting of lymphocytic leukemias were first observed in two patients due to insertional oncogenesis events. In both cases, RV integrations in the proximity of the LMO2 proto-oncogene promoted the transactivation of this gene through the LTR (long terminal repeat)
enhancer of the RV provirus. 9,10 Similar SAEs were then observed in other X1-SCID patients 3, 4, 11, 12 and also in X-CGD 7,13 and WAS patients 22 (Table 1) .
In contrast to the first ADA-SCID trials, in which no conditioning was used and where PEG-ADA was not stopped at the time of the infusion of tranduced CD34 + cells, 34 in subsequent trials a moderate conditioning was used, and PEG-ADA was suspended prior to gene therapy. 6, 25, 27 These modifications markedly improved the efficacy of the therapeutic approach. Moreover, in contrast to observations in other PIDs, in none of the ADA-SCID-treated patients have SAEs been reported (Table 1) , even though integration hotspots in different proto-oncogenes were identified. 5, 6, 25, 27, 34, 35 Due to the similarities of RV backbones used in the ADA-SCID trial and in other trials where insertional oncogenesis events were generated, differences in either the therapeutic transgene or most probably in the nature of the
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In vivo Gene Therapy for the treatment of PIDs. In the case of ADA-SCID and X1-SCID, the EF1α promoter was selected to drive expression of therapeutic transgenes. 24, [44] [45] [46] In the case of X-CGD, a chimeric promoter consisting of the fusion of regulatory sequences of the c-fes and Cathepsin G genes was used to promote a preferential expression of gp91 in myeloid cells. 47 In the WAS trial, 29 the selected promoter included the regulatory region of the WAS promoter aiming at driving a physiological expression of WASP in PB cells 48, 49 (see Table 1 ). -already used in the gene therapy of X-CGD patients 58 drives the expression of CD18. The Chim.hCD18-LV conferred phenotypic correction in mouse LAD-I leukocytes, which then expressed the heterodimer in their membrane and migrated to inflamed sites. Based on these experimental results it is expected that LAD-I will be added to the list of PIDs successfully treated by gene therapy. Hemoglobinopathies constitute the most prevalent RBC disorders.
T A B L E 1 Summary of gene therapy trials carried out with gamma-retroviral vectors (RV) and with self-inactivated lentiviral (SIN-LV) and gamma retroviral vectors (SIN-RV) trials in patients with primary immunodeficiencies
| GENE THERAPY IN RED BLOOD CELL DISORDERS
Approximately 5% of the world population carries a hemoglobin (Hb) alteration. 59 The incidence of hemoglobinopathies is even more frequent in areas where malaria is present because these pathologies, together with other RBC disorders such as PKD, confer resistance to the parasite infection. 60, 61 RBC disorders are caused by mutations in specific genes most of which have already been identified and cloned. These diseases can be cured by allogeneic HSCT, suggesting they are good candidates for hematopoietic gene therapy. As gene-corrected HSPCs from patients with RBC disorders do not develop advantage over diseased ones, full hematopoietic conditioning is required to eliminate endogenous HSCs, and to facilitate the engraftment of genetically corrected cells. 62, 63 In the case of hemoglobinopathies, protein levels of 10% to 30% are required to compensate the diseased phenotype of affected RBCs. 64 Additionally, the expression of globin proteins is tightly regulated and restricted to the erythroid lineage. Therefore, lineagespecific promoters were required in LVs designed for the treatment of hemoglobinopathies 69 More severe β 0 β 0 and severe β + β + phenotypes showed a 73% reduction in annualized transfusion requirements. Importantly, vector integration studies showed a polyclonal reconstitution with no specific clonal dominance that could reflect a leukemic process due to insertional mutagenesis, thus revealing the safety of these gene therapy approaches 69 (Table 2) .
A more recent trial was developed in Italy using the GLOBE LV. In this study, HSPCs were collected from PB after mobilization with G-CSF and plerixafor (an inhibitor of CXCR4/SDF1 chemokine signaling) and were infused intra-bone in patients treated with myeloablative conditioning with treosulfan plus thiotepa. This study showed rapid hematopoietic recovery with polyclonal multilineage engraftment of corrected cells, and a significant reduction and even discontinuation in the transfusion requirements. 72 SCD is caused by the sickle mutation in the β-globin gene, which induces the polymerization of hemoglobin tetramers upon deoxygenation. These polymers generate the characteristic sickle shape of erythrocytes inducing SCD symptoms, such as hemolytic anemia and stroke. 80 As observed in β-thal, preclinical studies showed that LVbased gene therapy could be a therapeutic option for SCD. Vectors Table 2 ).
The second family of RBC disorders in which gene therapy has been used in preclinical models includes erythroid metabolic disorders-such as PKD (where the glycolysis energetic pathway is affected)-and erythropoietic protoporphyria (EPP), which affects heme metabolism. was capable of fully correcting the PKD phenotype when more than 25% genetically corrected cells were transplanted. 89 A similar therapeutic threshold of corrected cells was reported in one PKD Basenji dog infused with foamy vector-corrected HSCs. 90 More recently, A therapeutic and clinically applicable LV that was as effective as the RV in curing the disease in PKD mice, which was generated in our laboratory, and showed a safe viral integration profile in mouse hematopoiesis. All FA proteins cooperate in a common pathway involved in the detection and repair of DNA inter-strand cross-links. The disruption of this key pathway leads to congenital abnormalities, BMF and cancer predisposition. 99 The inclusion of fludarabine (a potent immunosuppressive drug that does not cause DNA cross-linking) in conditioning regimens of FA patients markedly improved the outcome of transplanted patients. 100, 101 Nevertheless, HSCT in FA still leads to side effects, such as increased incidence of squamous cell carcinomas, probably due to the use of genotoxic conditioning regimens and GVHD [102] [103] [104] .
| GENE THERAPY IN INHERITED BONE MARROW FAILURE SYNDROMES
Gene therapy was thus considered a good alternative to HSCT for FA patients. However, difficulties in the development of FA gene therapy were derived from the low number of HSCs in these patients, 105 which limited the collection of clinically relevant numbers of HSCs either from the BM 106 or from G-CSF-mobilized PB 107, 108 from these patients. Despite these difficulties, the observation of hematological improvements in FA mosaic patients suggested that the correction of a low number of HSCs could be sufficient to restore the hematopoiesis of these patients. [109] [110] [111] This phenomenon was consid- Allogeneic HSCT represents the only curative treatment for DBA patients. Nevertheless, side effects such as graft failure and GVHD limit the efficacy of HSCT in these patients. As reported in FA, the observation of mosaic DBA patients suggests the proliferative advantage of reverted HSCs, 131, 132 reinforcing the idea that gene therapy should constitute a relevant therapeutic strategy in DBA.
Previous experimental studies have shown that both RVs and LVs can correct the characteristic phenotype of DBA cells. In this respect,
Hamaguchi et al showed proliferative defects in erythroid progenitors from patients with DBA and also that these defects could be ameliorated after complementation with RPS19-LVs. 133 Thereafter, the same group showed that the RV-mediated correction of CD34 + cells from DBA patients favored the erythro-differentiation of these cells, and reported their repopulating ability in immunodeficient mice. 134 Gene therapy studies conducted in a conditional RPS19 knockdown mouse model with SIN-LVs showed that the ectopic expression of RPS19 prevented the lethal BMF characteristic of these animals. 135 Because these studies used LVs harboring the strong SFFV promoter, subsequent studies were carried out with a more clinically relevant EFSα-RPS19 LV. 136 Based on preclinical gene therapy studies already conducted it is expected that gene therapy trials in patients with DBA will be developed in coming years.
Dyskeratosis congenita (DC) constitutes another IBMFS associated with mutations in any of the 15 genes related with the maintenance of telomere length. [137] [138] [139] [140] Three inherited forms of the disease have been described: X-linked, autosomal dominant and autosomal recessive. The main manifestations of the disease are ungual dystrophy, leukoplakia, cutaneous hyperpigmentation, as well as BMF, which appears in 80% of DC patients before the age of 30. 141, 142 In addition, patients can develop immunodeficiency, pulmonary fibrosis, kidney or liver failure and predisposition to develop myelodysplastic syndrome, acute myeloid leukemia and squamous cell carcinoma. 141 X-linked dyskeratosis congenita (X-DC) is one of the major variants of DC, and is caused by mutations in DKC1. 143 This gene encodes for dyskerin, a component of the telomerase complex. 144, 145 In cells derived from patients with X-DC, telomerase activity is compromised as a consequence of the defect in dyskerin. 144 Although allogeneic HSCT remains the only curative option for BMF of DC patients, the survival rate associated with the transplantation of these patients is still modest. 146, 147 The development of safe and effective gene therapy approaches would thus prevent the main complications associated with allogeneic transplantation.
In vivo gene therapy studies aiming at the reversion of the BMF of Trf-and Tert-deficient mice have used adeno-associated viral vectors (AAV9) carrying a healthy copy of Tert. HSCs using a CRISPR-Cas9/AAV6-based strategy for the integration of the IL2RG cDNA into the endogenous start codon of this gene. 164 Additional studies confirmed the possibility of editing SCD HSCs by the use of ZFNs combined with IDLVs to deliver the therapeutic cDNA into the β-globin gene. 165 Our group also showed the phenotypic correction of HSPCs from FA patients through the specific integration of FANCA in the AAVS1 locus using a similar combination of ZFN mRNAs and therapeutic donor IDLVs. Since non-homologous end joining (NHEJ) is the most efficient mechanism for the repair of DSBs, particularly in non-dividing cells, 174, 175 this strategy has been used in the first FDA approved gene editing trials with autologous HSCs. This trial aims at the treatment of HIV infection using ZFNs cleaving the CCR5 locus, that encodes a HIV receptor. 176 In the field of hemoglobinopathies, the knock-out of the BCL11A gene ( Figure 2D )-a repressor of fetal glo- 
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